$10 off your first order · Same-day shipping before 2 PM CT
CatalogCalculatorResearchAboutSupport
CatalogCalculatorResearchAboutSupport
Research notes
Research & Science

Retatrutide: The Triple Receptor Agonist Explained

Why a GIP / GLP-1 / glucagon triple agonist draws the attention it does, and how it differs from semaglutide and tirzepatide.

A new class of metabolic research compound

Retatrutide (development code LY3437943) is an investigational triple receptor agonist. In a single molecule it activates three receptors that regulate metabolism and energy balance: GIP, GLP-1, and the glucagon receptor. That third target is what sets it apart from the compounds that came before it.

The three pathways

  • GLP-1 (glucagon-like peptide-1): an incretin receptor tied to glucose-dependent insulin signaling and satiety pathways. This is the target of semaglutide.
  • GIP (glucose-dependent insulinotropic polypeptide): a second incretin receptor. Tirzepatide adds this to GLP-1, making it a dual agonist.
  • Glucagon receptor: linked in research to energy expenditure and hepatic lipid metabolism. Retatrutide adds this third arm.

Where retatrutide fits

The class moved one receptor at a time: semaglutide on GLP-1, tirzepatide adding GIP, retatrutide adding glucagon on top of both. It sits at the far end of that line, the first to engage all three receptors from a single molecule.

Research status

Retatrutide is investigational. It has moved through early- and mid-stage clinical research and into larger metabolic trials, but it is not an approved product. It is supplied here strictly as a lyophilized research compound. For laboratory research use only. Not for human consumption.

What the research has examined

Published work has characterized retatrutide's triple-agonist mechanism and its dose-dependent activity on metabolic endpoints. The preclinical discovery work (Coskun et al., *Cell Metabolism* 2022) established the molecule's simultaneous action at the GIP, GLP-1, and glucagon receptors. Mid-stage clinical trials then studied those endpoints in controlled settings, a 48-week phase 2 obesity trial (Jastreboff et al., *NEJM* 2023) and a phase 2 trial in type 2 diabetes (Rosenstock et al., *Lancet* 2023). These describe what the trials measured, and nothing more about the research compound sold here.

Limitations and open questions

  • Investigational only. Retatrutide is not approved by any regulator, and its long-term safety profile is not established.
  • Class-typical adverse events. Gastrointestinal effects were the most frequently reported events in trials, consistent with the incretin class.
  • The glucagon arm is the newest variable. Its long-term metabolic consequences remain an active, unresolved research question.

References

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. *N Engl J Med.* 2023;389:514–526. PubMed
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. *Lancet.* 2023;402:529–544. PubMed
  3. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. *Cell Metab.* 2022;34(9):1234–1247. PubMed